Telangiectasia, Hereditary Hemorrhagic Clinical Trial
Official title:
Studies of White Blood Cells Derived From HHT Patients
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an inherited vascular disease that leads to the development of dilated and fragile blood vessels. The study goal is to culture white blood cells that express the proteins mutated in HHT and examine in the laboratory to explain aspects of the HHT disease phenotype.
HHT is a vascular condition but many of the genes that are mutated to cause HHT (endoglin, ALK-1 and SMAD4) are also expressed in white blood cells. In this study, investigators will take blood samples from people with HHT, culture the white blood cells and study their properties in media prompting different types of differentiation, or infection of cell lines with Epstein Barr virus to provide cell lines which can be repeatedly studied. RNA and proteins will be extracted from these cells for study of white cell responses and association with expression levels of endoglin, ALK-1 and SMAD4. The investigators hypothesize that these cells which express "half-normal" endoglin, ALK-1 or SMAD4 will show differences when compared to normal white blood cells. It is also anticipated that that these findings may help to explain aspects of the HHT disease phenotype. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03227263 -
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).
|
Phase 3 | |
| Completed |
NCT00733655 -
Study of Histological Samples From Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Completed |
NCT00355108 -
ATERO : A Randomised Study With Tranexamic Acid in Epistaxis of Rendu Osler Syndrome
|
Phase 3 | |
| Completed |
NCT01507480 -
The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia
|
Phase 1 | |
| Completed |
NCT03910244 -
Pomalidomide for the Treatment of Bleeding in HHT
|
Phase 2 | |
| Completed |
NCT04108052 -
Diagnostic Value of Ultra-low Dose Thoracic Scanner for the Pulmonary Arteriovenous Malformation Detection in HHT Patient
|
N/A | |
| Recruiting |
NCT04976036 -
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
|
Phase 2 | |
| Completed |
NCT00684879 -
Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia
|
||
| Completed |
NCT00004648 -
Studies of Hereditary Hemorrhagic Telangiectasia
|
N/A | |
| Completed |
NCT00230672 -
Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs
|
||
| Completed |
NCT03954782 -
Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.
|
Phase 2 | |
| Completed |
NCT02484716 -
Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)
|
Phase 2 | |
| Recruiting |
NCT00230685 -
Case Notes Review on Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Terminated |
NCT02204371 -
Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia
|
Phase 2 | |
| Recruiting |
NCT00230620 -
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families
|
||
| Recruiting |
NCT02157987 -
Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose
|
Phase 1/Phase 2 | |
| Completed |
NCT01408030 -
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT00230659 -
Investigation of Coagulation Parameters in Hereditary Haemorrhagic Telangiectasia
|
||
| Withdrawn |
NCT00733629 -
Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia
|
||
| Recruiting |
NCT05933330 -
Hereditary Hemorrhagic Telangiectasia and Neurovascular Manifestations, in the Danish HHT Database
|